Healthcare Industry News: Millennium
News Release - July 6, 2010
EpiCept Corporation Names Rita Kelley Senior Director of MarketingTARRYTOWN, N.Y., July 6--(HSMN NewsFeed)--EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today that it has appointed Rita Kelley as the Company’s Senior Director of Marketing, a newly created position. A recognized leader in global pharmaceutical and biotechnology marketing, Ms. Kelley will play an integral role in execution of the North American launch and global marketing activities for Ceplene® (histamine dihydrochloride). A New Drug Application (NDA) for Ceplene as remission maintenance therapy in AML was filed with the Food and Drug Administration on June 29, 2010.
Ms. Kelley joins EpiCept from Millennium Pharmaceuticals, where she served as Senior Director, Oncology Global Strategic Marketing. From 2005 to 2009, she held several global leadership and development positions at Pfizer Inc, most recently as Senior Director, International Business Development where she focused on oncology and other therapeutic indications.
In her new position at EpiCept, Ms. Kelley will be responsible for the development and execution of promotional tactics in support of the planned North American launch of Ceplene. In addition to the recent NDA filing, a New Drug Submission for Ceplene is currently under active review by Health Canada. Ms. Kelley will also be responsible for activities in support of the commercial launch of Ceplene in major EU markets, working closely with EpiCept’s commercial partner in Europe, Meda AB.
“We are very pleased to welcome Rita to our marketing team,” said Bernie Tyrell, Senior Vice President, Sales and Marketing, for EpiCept. “Rita’s wealth of experience in oncology, sales management and customer engagement will be invaluable as we advance our global commercialization strategy for Ceplene.”
About EpiCept Corporation
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes EpiCept™ NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the United States or Canada, the risk that Ceplene will not achieve significant commercial success, the risk that any required post-approval clinical study for Ceplene will not be successful, the risk that we will not be able to maintain our final regulatory approval or marketing authorization for Ceplene, the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements, the risk that Azixa™ will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that clinical trials for EpiCept NP-1 or crolibulinTM will not be successful, the risk that EpiCept NP-1 or crolibulin will not receive regulatory approval or achieve significant commercial success, the risk that we will not be able to find a partner to help conduct the Phase III trials for EpiCept NP-1 on attractive terms, a timely basis or at all, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that we will not obtain approval to market any of our product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.
*Azixa is a registered trademark of Myriad Genetics, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.